FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Liraglutide may reduce kidney damage in diabetic disease by lowering cholesterol buildup in kidney filtering cells through a cell cleanup process controlled by mTOR and VMP1

Updated

Abstract

Liraglutide significantly reduces fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, and total cholesterol while increasing high-density lipoprotein cholesterol levels in diabetic kidney disease rats.

  • Liraglutide is associated with decreased renal damage in diabetic kidney disease models.
  • Autophagy activity may be enhanced by liraglutide, which is linked to improved cholesterol transport.
  • Liraglutide upregulates the expression of ABCA1, potentially alleviating cholesterol accumulation in the kidneys.
  • Both in vivo and in vitro findings indicate that liraglutide reduces podocyte cholesterol accumulation.
  • The reduction of cholesterol accumulation in podocytes is mediated through the mTOR/VMP1 pathway.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free